Tirzepatide: Dosage, Benefits & Research Guide
Also known as: LY3298176, GIP/GLP-1 RA
What is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered to act as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By engaging both incretin pathways, it has been investigated in research models for effects on insulin secretion, glucagon suppression, gastric emptying, appetite signaling, and adipose tissue metabolism. It is frequently used as a comparator alongside GLP-1-only agonists such as semaglutide and triple agonists such as retatrutide in metabolic research. Supplied as a lyophilized powder for in-vitro and laboratory research use only; not for human consumption.
Tirzepatide Research Applications
In published and preclinical research, Tirzepatide has been studied across the following areas:
- GIP/GLP-1 dual receptor agonist research
- Glucose regulation and insulin sensitivity studies
- Body composition and weight management research
- Comparative incretin research
Tirzepatide in Research: Reconstitution & Study Concentrations
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied extensively in the SURPASS and SURMOUNT clinical programs. In a laboratory setting the lyophilized peptide is reconstituted with bacteriostatic water; the working concentration is set by the solvent volume and the research model. Tirzepatide is not approved for human use in the form sold here and is supplied strictly for research.
Worked example: a 10mg vial reconstituted with 2 mL of bacteriostatic water yields 5.00 mg/mL.
Open the reconstitution calculatorHow Tirzepatide Compares
Researchers frequently evaluate Tirzepatide alongside related compounds:
- Tirzepatide vs Retatrutide — triple vs. dual agonist